<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815997</url>
  </required_header>
  <id_info>
    <org_study_id>2008-28</org_study_id>
    <nct_id>NCT00815997</nct_id>
  </id_info>
  <brief_title>Novel Angioplasty Using Coronary Accessor</brief_title>
  <acronym>NAUSICA</acronym>
  <official_title>Novel Angioplasty USIng Coronary Accessor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NAUSICA Investigators</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NPO International TRI Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NAUSICA Investigators</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the advantage of using a 4Fr guiding catheter over a 6 Fr, frequencies of
      radial artery occlusion after transradial coronary intervention (TRI) will be evaluated.
      Radial artery occlusion rate in 4 Fr TRI group is expected to be not more than that in 6Fr
      groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prerequisites for TRI were a sufficiently pulsating radial artery and presence of an ulnar
      pulse with a sufficient palmar arch, as evidenced by the absence of digital ischemia
      according to the Allen's test. Exclusion criteria for the current study included planned use
      of a cutting balloon, rotational atherectomy, directional coronary atherectomy, and
      intravascular ultrasound, which were not compatible with 4-Fr catheter.

      Patency of the radial artery after TRI will be evaluated by pulsation of the radial artery,
      and frequencies of which will be compared between those receiving 4Fr vs 6 Fr coronary
      interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1, 2009</start_date>
  <completion_date type="Actual">December 31, 2010</completion_date>
  <primary_completion_date type="Actual">December 31, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Radial Artery Occlusion</measure>
    <time_frame>within 2 days after TRI</time_frame>
    <description>The primary endpoint was radial artery occlusion the day after TRI, defined as the absence of a radial pulse confirmed by a reverse Allen's test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Successful PCI</measure>
    <time_frame>within 2 days after TRI</time_frame>
    <description>Procedural success was defined as a postprocedural residual stenosis of less than 20%, and a thrombolysis in myocardial infarction (TIMI) grade 3 angiographic flow without MACE during in-hospital follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Measure Adverse Cardiac Event (MACE)</measure>
    <time_frame>within 2 days after TRI</time_frame>
    <description>Defined as a composite of cardiac death, myocardial infarction, and target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Access-site Complications</measure>
    <time_frame>within 2 days after TRI</time_frame>
    <description>Access-site-related complications were defined as bleeding, pseudoaneurysm, arteriovenous fistula, and occlusion of the radial artery, which were considered to be major if they were associated with a vascular repair or a blood transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy Time Used for the Procedure</measure>
    <time_frame>At the end of TRI</time_frame>
    <description>Fluoroscopy time used for the procedure (minutes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Dye Volume Used for the Procedure</measure>
    <time_frame>At the end of TRI</time_frame>
    <description>Contrast dye volume used for the procedure (mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Used for the Procedure</measure>
    <time_frame>At the end of TRI</time_frame>
    <description>Time used for the procedure (minutes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Used for Hemostasis</measure>
    <time_frame>within 2 days afterTRI</time_frame>
    <description>Time Used for Hemostasis (minutes).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Patency of the Radial Artery</condition>
  <arm_group>
    <arm_group_label>6-Fr TRI (transradial coronary intervention)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>TRI will be performed using a 6-Fr guiding catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-Fr TRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TRI will be performed using a 4-Fr guiding catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI (percutaneous coronary intervention)</intervention_name>
    <description>PCI will be performed via the radial artery.</description>
    <arm_group_label>4-Fr TRI</arm_group_label>
    <arm_group_label>6-Fr TRI (transradial coronary intervention)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prerequisites for transradial intervention were a sufficiently pulsating radial artery
             and presence of an ulnar pulse with a sufficient palmar arch, as evidenced by the
             absence of digital ischemia according to the Allen's test.

        Exclusion Criteria:

          -  Exclusion criteria included planned use of a cutting balloon, rotational atherectomy,
             directional coronary atherectomy, and intravascular ultrasound, which were not
             compatible with 4-Fr catheter.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vice Preseident, Shonan Kamakura General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>AP</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences</name>
      <address>
        <city>Secunderabad</city>
        <state>AP</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tosei General Hospital</name>
      <address>
        <city>Seto</city>
        <state>Aichi</state>
        <zip>489-8652</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chibaken Saiseikai Narashino Hospital</name>
      <address>
        <city>Narashino</city>
        <state>Chiba</state>
        <zip>275-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin-Koga Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kin-ikyo Central Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>007-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurakai Takahashi Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>654-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>665-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Atsugi Hospital</name>
      <address>
        <city>Atsugi</city>
        <state>Kanagawa</state>
        <zip>243-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Rosai Hospital</name>
      <address>
        <city>Yatsushiro</city>
        <state>Kumamoto</state>
        <zip>866-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aomori Prefectural Central Hospital</name>
      <address>
        <city>Aomori</city>
        <zip>030-8553</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Heart Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Kujo Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>601-8453</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Pai-Tou</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Japan</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2008</study_first_posted>
  <results_first_submitted>August 21, 2018</results_first_submitted>
  <results_first_submitted_qc>February 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2019</results_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NAUSICA Investigators</investigator_affiliation>
    <investigator_full_name>Shigeru Saito</investigator_full_name>
    <investigator_title>Vice President, Shonan Kamakura Genaral Hospital</investigator_title>
  </responsible_party>
  <keyword>radial artery</keyword>
  <keyword>transradial intervention</keyword>
  <keyword>stent</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>6 Fr TRI</title>
          <description>TRI will be performed using a 6-Fr guiding catheter.</description>
        </group>
        <group group_id="P2">
          <title>4-Fr TRI</title>
          <description>TRI will be performed using a 4-Fr guiding catheter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The trial was powered to show the noninferiority of 4-Fr compared with 6-Fr in achieving the primary endpoint of radial artery patency, with a 2-sided alpha level of 0.05. Assuming a radial artery occlusion rate of 1% in the 4-Fr and 6% in the 6-Fr, with a noninferiority margin, δ, of 5%.</population>
      <group_list>
        <group group_id="B1">
          <title>6 Fr TRI</title>
          <description>TRI will be performed using a 6-Fr guiding catheter.</description>
        </group>
        <group group_id="B2">
          <title>4-Fr TRI</title>
          <description>TRI will be performed using a 4-Fr guiding catheter.
TRI using a 4-Fr guiding catheter: TRI will be performed using a 4-Fr guiding catheter.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="11"/>
                    <measurement group_id="B2" value="68" spread="11"/>
                    <measurement group_id="B3" value="68" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Radial Artery Occlusion</title>
        <description>The primary endpoint was radial artery occlusion the day after TRI, defined as the absence of a radial pulse confirmed by a reverse Allen's test.</description>
        <time_frame>within 2 days after TRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6 Fr TRI</title>
            <description>TRI will be performed using a 6-Fr guiding catheter.</description>
          </group>
          <group group_id="O2">
            <title>4-Fr TRI</title>
            <description>TRI will be performed using a 4-Fr guiding catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Radial Artery Occlusion</title>
          <description>The primary endpoint was radial artery occlusion the day after TRI, defined as the absence of a radial pulse confirmed by a reverse Allen's test.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Successful PCI</title>
        <description>Procedural success was defined as a postprocedural residual stenosis of less than 20%, and a thrombolysis in myocardial infarction (TIMI) grade 3 angiographic flow without MACE during in-hospital follow-up.</description>
        <time_frame>within 2 days after TRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6-Fr TRI (Transradial Coronary Intervention)</title>
            <description>TRI will be performed using a 6-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
          <group group_id="O2">
            <title>4-Fr TRI</title>
            <description>TRI will be performed using a 4-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Successful PCI</title>
          <description>Procedural success was defined as a postprocedural residual stenosis of less than 20%, and a thrombolysis in myocardial infarction (TIMI) grade 3 angiographic flow without MACE during in-hospital follow-up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Measure Adverse Cardiac Event (MACE)</title>
        <description>Defined as a composite of cardiac death, myocardial infarction, and target lesion revascularization</description>
        <time_frame>within 2 days after TRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6-Fr TRI (Transradial Coronary Intervention)</title>
            <description>TRI will be performed using a 6-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
          <group group_id="O2">
            <title>4-Fr TRI</title>
            <description>TRI will be performed using a 4-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Measure Adverse Cardiac Event (MACE)</title>
          <description>Defined as a composite of cardiac death, myocardial infarction, and target lesion revascularization</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Access-site Complications</title>
        <description>Access-site-related complications were defined as bleeding, pseudoaneurysm, arteriovenous fistula, and occlusion of the radial artery, which were considered to be major if they were associated with a vascular repair or a blood transfusion.</description>
        <time_frame>within 2 days after TRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6-Fr TRI (Transradial Coronary Intervention)</title>
            <description>TRI will be performed using a 6-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
          <group group_id="O2">
            <title>4-Fr TRI</title>
            <description>TRI will be performed using a 4-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Access-site Complications</title>
          <description>Access-site-related complications were defined as bleeding, pseudoaneurysm, arteriovenous fistula, and occlusion of the radial artery, which were considered to be major if they were associated with a vascular repair or a blood transfusion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluoroscopy Time Used for the Procedure</title>
        <description>Fluoroscopy time used for the procedure (minutes).</description>
        <time_frame>At the end of TRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6-Fr TRI (Transradial Coronary Intervention)</title>
            <description>TRI will be performed using a 6-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
          <group group_id="O2">
            <title>4-Fr TRI</title>
            <description>TRI will be performed using a 4-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluoroscopy Time Used for the Procedure</title>
          <description>Fluoroscopy time used for the procedure (minutes).</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="11"/>
                    <measurement group_id="O2" value="13" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast Dye Volume Used for the Procedure</title>
        <description>Contrast dye volume used for the procedure (mL).</description>
        <time_frame>At the end of TRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6-Fr TRI (Transradial Coronary Intervention)</title>
            <description>TRI will be performed using a 6-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
          <group group_id="O2">
            <title>4-Fr TRI</title>
            <description>TRI will be performed using a 4-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast Dye Volume Used for the Procedure</title>
          <description>Contrast dye volume used for the procedure (mL).</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="68"/>
                    <measurement group_id="O2" value="87" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Used for the Procedure</title>
        <description>Time used for the procedure (minutes).</description>
        <time_frame>At the end of TRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6-Fr TRI (Transradial Coronary Intervention)</title>
            <description>TRI will be performed using a 6-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
          <group group_id="O2">
            <title>4-Fr TRI</title>
            <description>TRI will be performed using a 4-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Used for the Procedure</title>
          <description>Time used for the procedure (minutes).</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="22"/>
                    <measurement group_id="O2" value="37" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Used for Hemostasis</title>
        <description>Time Used for Hemostasis (minutes).</description>
        <time_frame>within 2 days afterTRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6-Fr TRI (Transradial Coronary Intervention)</title>
            <description>TRI will be performed using a 6-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
          <group group_id="O2">
            <title>4-Fr TRI</title>
            <description>TRI will be performed using a 4-Fr guiding catheter.
PCI (percutaneous coronary intervention): PCI will be performed via the radial artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Used for Hemostasis</title>
          <description>Time Used for Hemostasis (minutes).</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" spread="238"/>
                    <measurement group_id="O2" value="237" spread="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>6 Fr TRI</title>
          <description>TRI will be performed using a 6-Fr guiding catheter.</description>
        </group>
        <group group_id="E2">
          <title>4-Fr TRI</title>
          <description>TRI will be performed using a 4-Fr guiding catheter.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sigeru Saito, MD, Principal Investigator</name_or_title>
      <organization>NPO International TRI Network</organization>
      <phone>+81-467-461717 ext 10490</phone>
      <email>saito@shonankamakura.or.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

